Houston Methodist brings new scientific discoveries to patients as rapidly as possible through the full cycle of a cure from bench research, to prototyping and production, to clinical trials and FDA approval. Houston Methodist has a $30 million product development fund to navigate promising technologies through this translational pipeline and facilitate a technology transfer hand off to the market for delivery to patients. Our focus is on achieving market adoption and compliance with safety, laws and regulations to give patients quicker access to safe and effective therapies.

Our interdisciplinary research teams identify promising discoveries early in their life cycle and accelerate them through the development process, positioning them to make the giant leap from idea to clinic. A few of those projects include design of an artificial mitral valve to improve patient outcomes after surgery, a diagnostic test to enhance liver transplant outcomes, a magnetic brain stimulation cap for stroke patients and a comprehensive software program used to improve planning for craniomaxillofacial surgeries. In addition, the Center for Rapid Device Translation guides clients through safety studies and regulatory approval pathways to bring new medical devices to market. They provide full-service expertise and study execution to achieve preclinical device validation and open the door for early phase clinical testing, should it be required by a regulatory agency.